{"id":"W2887327758","doi":"10.1158/1538-7445.am2018-lb-265","title":"Abstract LB-265: The novel oral Chk1 inhibitor, SRA737, is active in both PARP inhibitor resistant and <i>CCNE1</i> amplified high grade serous ovarian cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alterra Power (Canada)","funders":"","keywords":"Cancer research; CHEK1; PARP inhibitor; Olaparib; Cancer; Medicine; Cell cycle; Biology; Cell cycle checkpoint; Internal medicine; Polymerase; Poly ADP ribose polymerase; DNA; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001082227,0.0003059474,0.0003111182,0.0002506457,0.0001599555,0.0002536442,0.0002288765,0.000198291,0.002328335],"category_scores_gemma":[0.00007517332,0.00009571491,0.0002283272,0.0002055761,0.0001673624,0.000168325,0.0001008199,0.0006358523,0.0004110115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000230625,"about_ca_system_score_gemma":0.0004128076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001647979,"about_ca_topic_score_gemma":0.003467404,"domain_scores_codex":[0.9999218,0.00001434133,0.00000649643,0.00001205238,0.00002049255,0.00002475381],"domain_scores_gemma":[0.9999439,0.00000825144,0.00001119606,0.000005636101,0.00000599739,0.00002508535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002112845,0.0008818045,0.0007304472,0.0001912724,0.00004568204,0.0001886059,0.00002356728,0.0003733852,0.9728817,0.0002334356,0.001204245,0.02113301],"study_design_scores_gemma":[0.0008151319,0.0125703,0.01056377,0.00002008054,0.00012965,0.0009681981,0.00005120063,0.001846719,0.9645768,0.00005665113,0.008387051,0.00001445015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991443,0.003664908,0.0006904927,0.0001734843,0.00004817771,0.00006822364,0.0006602449,0.0001986632,0.003052711],"genre_scores_gemma":[0.9948,0.001378117,0.0008095787,0.0000567694,0.00001483129,0.00003565331,0.001030303,0.00001377582,0.00186108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002328335,"threshold_uncertainty_score":0.007789075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1113094138338781,"score_gpt":0.4127934726606565,"score_spread":0.3014840588267784,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}